Cenra Healthcare and Moderna Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

Cenra Healthcare, the sales and marketing arm of Cenra Inc. (TWSE:3716) and Moderna, Inc. (Nasdaq: MRNA), today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna’s mRNA respiratory vaccine portfolio in Taiwan, including Moderna’s COVID-19 vaccine, Spikevax®. 

Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna’s mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on the financial terms of the deal are being disclosed.

“We are excited to partner with Cenra Healthcare, a trusted leader in Taiwan's medical industry with extensive expertise in infectious diseases and respiratory products," said Joyce Lee, General Manager of Moderna in Taiwan. "Their strong presence in the market will help ensure broader access to our vaccines. We are committed to advancing public health initiatives across Taiwan, and this partnership will enable us to expand our educational efforts around our COVID-19 vaccine and future portfolio, especially as respiratory diseases continue to pose a global threat."

“At Cenra, we are proud and excited to partner with a global innovator like Moderna to contribute to Taiwan’s public health efforts,” said Lucas Lin, General Manager, Cenra Healthcare. “With our leading market presence and deep understanding of Taiwan’s healthcare landscape, along with Moderna’s world-class mRNA vaccines, Cenra Healthcare is well-equipped to support Taiwan’s immunization programs by ensuring access through seamless collaboration with healthcare providers and communities.”